HK1143313B - Sustained release of microcrystalline peptide suspensions - Google Patents

Description

BACKGROUND OF THE INVENTION

There is frequently a need to deliver biologically active peptides to animals and humans in formulations providing a sustained release of the active principle. Such formulations may be provided by incorporating the active principle in biodegradable and biocompatible polymers in form of microcapsules, microgranules or implantable rods, or alternatively using mechanical devices such as micropumps or non-biodegradable containers. If the peptide is highly soluble in aqueous media, it can be formulated as a complex with non-degradable polymers such as cellulose derivatives, or mixed with polymer solutions, which form a gel upon parenteral injection, from which the active peptide is slowly released.

All the above-mentioned formulations have drawbacks and limitations, such as the large volume of suspending fluids or the need to remove the non-degradable device. In the case of gel forming peptides, there is frequently a problem of bioavailability, which interferes with the desired sustained action of the active principle.

Some of the problems due to physico-chemical aspects of peptides have been described in article by R. Deghenghi "Antarelix" in Treatment with GnRH Analogs: Controversies and Perspectives", edited by M. Filicori and C. Flamigni, The Parthenon Publishing Group, New York and London 1996, pages 89-91. Additional problems were illustrated by J. Rivier "GnRH analogues towards the next millennium" in GnRH Analogues, edited by B. Lunenfeld, The Parthenon Publishing Group, New York and London 1999, pages 31-45 and by other workers such as M.F. Powell et al. "Parenteral Peptide Formulations: Chemical and Physical Properties of Native LHRH and Hydrophobic Analogues in Aqueous Solution" in Pharmaceutical Research, Vol. 8, 1258-1263 (1991).

Accordingly, there is a need for new formulations and methods of administration that avoid these problems, and this need is addressed by the present invention.

DE 43 42 092 A discloses long-working injectable suspensions comprising low solubility salts of LHRH analogues, in particular cetrorelix embonate.

SUMMARY OF THE INVENTION

The invention relates to a method of preventing gel formation as defined in claim 1.

The invention also relates to a fluid, milky microcrystalline aqueous suspension as defined in claim 2.

The avoidance of a gel enables an injectable suspension to be formulated. When these aqueous suspensions are injected parenterally (i.e., subcutaneously or intramuscularly) into a mammal, such as a human, a sustained release of the hydrophobic peptide over time is obtained.

Preferably, GnRH antagonists are selected from the groups of Azaline B, Abarelix, Antide, Ganirelix, Cetrorelix, or FE200486 in the form of trifluoroacetate or sulfate salts. Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Hci-Leu-Ilys-Pro-D-Ala-NH₂ trifluoroacetate and Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Hci-Leu-Ilys-Pro-D-Ala-NH₂ sulfate are the most preferred compounds.

The hydrophobic peptide salt is preferably suspended in the aqueous medium at a concentration of equal to or higher than 25 mg/ml and has a molar ratio of at least 1.6:1 of acid:peptide. The peptide salt is at least partially in the form of needles having a particle size of between about 5 and 150 µm.

If desired, the aqueous suspension can contain an isotonic agent, such as mannitol. Also, the aqueous suspension may contain a pharmaceutically acceptable excipient. Advantageously, the suspension is dried to a lyophilized state which can be reconstituted by mixing with water or a buffer solution. Lyophilized compositions comprising these dried suspensions, as well as the methods for making the dried suspensions, represent additional embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

• Figure 1 is a graph which illustrates the pharmacodynamic effect (testosterone suppression) obtained by subcutaneous injection in rats of a suspension of teverelix® trifluoroacetate according to the invention; and
• Figure 2 is graph which illustrates the sustained release of the peptide teverelix® for several weeks in rats injected with the suspension of teverelix® trifluoroacetate according to the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

We made the unexpected discovery that a highly concentrated aqueous suspension of the peptide of the formula Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Hci-Leu-Lys(iPr)-Pro-D-Ala-NH₂ (teverelix®, a GnRH antagonist) as a trifluoroacetate (TFA) or sulfate salt does not, as might be expected by its hydrophobic character, form a gel but instead forms a microcrystalline milky suspension which is easy to inject parenterally in animals or humans, and which releases the active principle over several weeks (see Figures 1 and 2). Such behavior is not elicited by other salts such as the acetate, which result in the expected, but unwanted, formation of gels with poor bioavailability in vivo.

Our invention represents a simple and elegant solution of the problem of how to suppress gelation of hydrophobic peptides while obtaining a prolonged sustained delivery of such peptides in form of microcrystalline highly concentrated suspensions.

An additional advantage of our discovery is the small volume of such suspensions, allowing parenteral injections through a fine needle and thus improving the local tolerance of the injected material. In such injections, the amount of peptide ranges from about 0.1 to 5mg per kg body weight of the mammal to which the suspension is to be administered.

The amount of counter-ion is preferably that which is in excess of what is necessary to form the salt. This amount is typically at least 1.6 mol acid/mole peptide and preferably 2mol/mol or greater. In addition, the injectable suspension should be concentrated to obtained the most desirable release profiles. By concentrated, we mean that the amount of peptide should be above 2.5% by weight of the overall formulation.

The suspensions can be dried by freeze-drying or spray drying to form lyophilized compositions that can be stored as is and reconstituted with water or buffer solutions when an injectable formulation is to be prepared.

EXAMPLES Example 1

200µL of 5% mannitol were added to approximately 15mg of the LHRH antagonist teverelix® trifluoroacetate. The mixture was stirred using vortex during one minute and a flowing milky pearly suspension was obtained. The suspension is made of microcrystals of about 10µm length. Microcrystals may clump together to form urchin like structures. The suspension was injected in rats (1mg) sub-cutaneously and provided the pharmacodynamic effect of testosterone suppression for more than 45 days (Figure 1). The pharmacokinetic analysis showed a sustained release of the peptide for several weeks (Figure 2).

Example 2

200µL of water were added to approximately 15mg of the LHRH antagonist teverelix® trifluoroacetate. The mixture was stirred using vortex during one minute and a flowing milky pearly suspension was obtained.

Example 3

200µL of water were added to approximately 15mg of the LHRH antagonist teverelix® acetate. The mixture was stirred using vortex during one minute and a transparent gel was obtained. The addition of 20µL of TFA (3mols/mol) to the gel resulted in the formation of a fluid, flowing milky pearly suspension.

Example 4

200µL of 100mM TFA were added to approximately 15mg of the LHRH antagonist teverelix® acetate (2mols/mol) to obtain a flowing milky suspension. In addition, mixing 200µL of 75mM TFA with approximately 15 mg of the LHRH antagonist teverelix® acetate (1.5mol/mol) resulted in a transparent gel being obtained after mixing. In another study, 100µL of TFA of various concentrations were added to 7.5mg of the LHRH antagonist teverelix® acetate, with the TFA/Teverelix molar ratio ranging from 1 to 3. A flowing milky suspension was obtained with molar ratios of ≥ 1.6, whereas gels were obtained at other molar ratios.

Example 5

200µL of 150mM TFA were added to amounts of the LHRH antagonist teverelix® acetate ranging from 5 to 30mg (concentration ranging from 25 to 150mg/ml). A flowing milky suspension was obtained with concentrations up to 100mg/ml.

Example 6

200µL of 150mM TFA were added to approximately 15mg of the LHRH antagonist teverelix® acetate (3mols/mol) and a flowing milky suspension was obtained after mixing. The suspension was freeze-dried over-night. 200µL of water or 5% mannitol were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution.

Example 7

1mL of 150mM TFA were added to approximately 75 mg of the LHRH antagonist teverelix® acetate (3mols/mol) and a flowing milky suspension was obtained after mixing. The suspension was freeze-dried over-night. 1mL of water and 0.2M acetate buffer pH 4.0 were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution. These suspensions were stable for at least 3 days at room temperature.

Example 8

100µL of a 250mM H₂SO₄ were added to 7.5mg of the LHRH antagonist teverelix® acetate (5mols/mol) and a flowing milky suspension was obtained after several hours. The suspension is made of microcrystals of about 100µm length. Microcrystals may assemble together to form urchin like structures. The suspension was freeze-dried over-night. 100µL of water or 5% mannitol were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution.

Claims (13)

1. A method of preventing gel formation of a GnRH antagonist which comprises contacting the GnRH antagonist with a counter-ion derived from trifluoroacetic acid or sulfuric acid in an amount and at a molar ratio sufficient to provide a fluid, milky microcrystalline aqueous suspension of the GnRH antagonist without formation of a gel.
2. A fluid, milky microcrystalline aqueous suspension of a GnRH antagonist and a counter-ion derived from trifluoroacetic acid or sulfuric acid in water, wherein the peptide GnRH antagonist and counter-ion are present in amounts and at a molar ratio sufficient to form, upon mixing, the suspension without formation of a gel.
3. A method of preparing a sustained release formulation of a GnRH antagonist which comprises contacting the GnRH antagonist with a counter-ion derived from trifluoroacetic acid or sulfuric acid, wherein the GnRH antagonist and counter-ion are present in amounts and at a molar ratio sufficient to form, upon mixing, the suspension without formation of a gel.
4. The method of claims 1 or 3 or the suspension of claim 2 in which the GnRH antagonist is selected from the group of Azaline B, Abarelix, Antide, Ganirelix, Cetroelix, Teverelix, or FE200486
5. The method of claims 1 or 3 or the suspension of claim 2 in which the GnRH antagonist salt is suspended in the aqueous medium at a concentration of equal to or higher than 25 mg/ml.
6. The method of claims 1 or 3 or the suspension of claim 2 in which the aqueous suspension contains an isotonic agent.
7. The method or suspension of claim 6 in which the isotonic agent is mannitol.
8. The method of claims 1 or 3 or the suspension of claim 2 in which the aqueous suspension contains a pharmaceutically acceptable excipient.
9. The method of claim 1 or claim 3 in which the aqueous suspension is obtained extemporaneously from a lyophilized peptide salt.
10. The suspension of claim 2 wherein the microcrystals are in the form of needles having a particle size of between 5 and 150 µm.
11. A lyophilized composition comprising the dried suspension of claim 2.
12. A method of preparing a dried composition according to claim 11 which comprises a method as claimed in claim 1 followed by freeze-drying or spray-drying to obtain the composition.
13. A method of preparing an injectable fluid, milky, microcrystalline aqueous suspension of a hydrophobic peptide which comprises reconstituting with water or a buffer solution the lyophilized composition of claim 11.